Citigroup’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-390
Closed -$2K 7890
2020
Q4
$2K Hold
390
﹤0.01% 7262
2020
Q3
$2K Hold
390
﹤0.01% 7343
2020
Q2
$2K Sell
390
-5,000
-93% -$31.6K ﹤0.01% 7441
2020
Q1
$20K Sell
5,390
-600
-10% -$2.98K ﹤0.01% 6713
2019
Q4
$37K Buy
5,990
+470
+9% +$3.46K ﹤0.01% 6576
2019
Q3
$47K Buy
5,520
+270
+5% +$2.01K ﹤0.01% 6178
2019
Q2
$35K Buy
5,250
+4,530
+629% +$38.8K ﹤0.01% 6770
2019
Q1
$6K Sell
720
-2,650
-79% -$27.4K ﹤0.01% 7400
2018
Q4
$54K Buy
3,370
+1,870
+125% +$41.1K ﹤0.01% 6182
2018
Q3
$50K Buy
1,500
+620
+70% +$15.9K ﹤0.01% 6523
2018
Q2
$20K Buy
880
+30
+4% +$711 ﹤0.01% 6928
2018
Q1
$25K Buy
850
+600
+240% +$17.6K ﹤0.01% 6637
2017
Q4
$7K Buy
+250
New +$7.76K ﹤0.01% 7165

Citigroup's AVEO Position: Q1 2023 in Review

Citigroup sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 775 shares — an estimated $11.6K sold.

Citigroup first reported a position in AVEO in Q2 2013 and held it in 31 quarters. The position peaked at $128K in Q3 2018. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

  • Citigroup reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 775 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $11.6K.
  • Citigroup first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 31 quarters.
  • Citigroup's AVEO Pharmaceuticals, Inc. position peaked at $128K in Q3 2018.
  • 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.